Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
Can J Physiol Pharmacol. 2010 Mar;88(3):204-19. doi: 10.1139/Y09-135.
The mitochondria are unique cellular organelles that contain their own genome and, in conjunction with the nucleus, are able to transcribe and translate genes encoding components of the electron transport chain (ETC). To do so, the mitochondria must communicate with the nucleus via the production of reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), which are produced as a byproduct of aerobic respiration within the mitochondria. Mitochondrial signaling is proposed to be altered in cancer cells, where the mitochondria are frequently found to harbor mutations within their genome and display altered functional characteristics leading to increased glycolysis. As signaling molecules, ROS oxidize and inhibit MAPK phosphatases resulting in enhanced proliferation and survival, an effect particularly advantageous to cancer cells. In terms of transcriptional regulation, ROS affect the phosphorylation, activation, oxidation, and DNA binding of transcription factors such as AP-1, NF-kappaB, p53, and HIF-1alpha, leading to changes in target gene expression. Increased ROS production by defective cancer cell mitochondria also results in the upregulation of the transcription factor Ets-1, a factor that has been increasingly associated with aggressive cancers.
线粒体是独特的细胞细胞器,它们含有自己的基因组,并与细胞核一起,能够转录和翻译编码电子传递链(ETC)组件的基因。为此,线粒体必须通过产生活性氧物种(ROS)如过氧化氢(H2O2)与细胞核进行通信,这些 ROS 是在线粒体中进行需氧呼吸的副产物。据推测,癌细胞中线粒体信号发生改变,线粒体基因组中经常发现存在突变,并显示出改变的功能特征,导致糖酵解增加。作为信号分子,ROS 氧化并抑制 MAPK 磷酸酶,导致增殖和存活增强,这对癌细胞尤其有利。在转录调节方面,ROS 影响转录因子如 AP-1、NF-kappaB、p53 和 HIF-1alpha 的磷酸化、激活、氧化和 DNA 结合,导致靶基因表达的变化。有缺陷的癌细胞线粒体产生的 ROS 增加也导致转录因子 Ets-1 的上调,Ets-1 因子与侵袭性癌症的关系越来越密切。
Can J Physiol Pharmacol. 2010-3
Med Hypotheses. 2005
Biochimie. 2007-9
Biochemistry. 2005-5-10
Cancer Metastasis Rev. 2006-12
Arterioscler Thromb Vasc Biol. 2007-4
Cancers (Basel). 2022-10-5
Mol Cell Biol. 2018-11-28
J Exp Clin Cancer Res. 2018-3-16
Biochem Pharmacol. 2017-4-15